| Literature DB >> 28626527 |
David Schaller1, Stefanie Hagenow2, Gina Alpert2, Alexandra Naß1, Robert Schulz1, Marcel Bermudez1, Holger Stark2, Gerhard Wolber1.
Abstract
In this study, we report a ligand-centric data mining approach that guided the identification of suitable target profiles for treating obesity. The newly developed method is based on identifying target pairs for synergistic positive effects and also encompasses the exclusion of compounds showing a detrimental effect on obesity treatment (off-targets). Ligands with known activity against obesity-relevant targets were compared using fingerprint representations. Similar compounds with activities to different targets were evaluated for the mechanism of action since activation or deactivation of drug targets determines the pharmacological effect. In vitro validation of the modeling results revealed that three known modulators of melanin-concentrating hormone receptor 1 (MCHR1) show a previously unknown submicromolar affinity to the histamine H3 receptor (H3R). This synergistic activity may present a novel therapeutic option against obesity.Entities:
Keywords: Multitarget drugs; fingerprints; histamine H3 receptor; melanin-concentrating hormone receptor 1; obesity
Year: 2017 PMID: 28626527 PMCID: PMC5467185 DOI: 10.1021/acsmedchemlett.7b00118
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345